Can Two Dietary Interventions Maintain Weight Loss for 12 Months After GLP-1 Therapy in Adults With Overweight/Obesity? (DIET-SLIM)

July 17, 2026 updated by: Knut Mai

DIETary Strategies to stabiLize Incretin-based Weight Loss in Obesity Management

So far, treatment with semaglutide (Wegovy) for therapy of obesity demonstrates substantial effects. However, most patients do not desire life-long pharmaceutical therapy or discontinue this treatment regime. This is accompanied by rapid weight regain. Moreover, numerous patients are open to an intermittent therapy.

This trial aims to investigate whether two diet interventions can keep weight stable after weight loss with semaglutide in people with obesity or overweight.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

292

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • BMI ≥ 30 kg/m² OR ≥ 27 kg/m² with concomitant cardiometabolic risk factors (metabolic syndrome, elevated blood pressure, dyslipidemia or impaired glucose metabolism (but not type 2 diabetes)

Exclusion Criteria:

  • BMI ≥ 45 kg/m²
  • intake of glucose lowering drugs
  • presence of incretin-based treatment
  • acute severe CVD
  • uncontrolled hypertension
  • severe hepatic or renal diseases
  • severe food allergy or malabsorption disease
  • active cancer
  • condition after bariatric surgery
  • history of eating disorder
  • concurrent pregnancy and breastfeeding

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: NutriAct plus
Adults with obesity who have lost >= 7% of their body weight with semaglutide therapy over 3-5 months and who will follow NutriAct plus for 12 months
Behavioral: NutriAct plus
Dietary pattern, vegetarian version of the NutriAct pattern
Other: Rescue VLCD
Adults with obesity who have lost >= 7% of their body weight with semaglutide therapy over 3-5 months and who will receive rescue VLCD in case of weight regain for 12 months
Behavioral: Rescue VLCD
Very low calorie diet as full meal replacement over 28 days in case of weight regain

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
weight in kg
Time Frame: body weight in kg after weight loss (3 to 5 months) and dietary intervention (12 months)
body weight in kg after weight loss (3 to 5 months) and dietary intervention (12 months)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Knut Mai

Collaborators

Institute for Clinical and Experimental Medicine
University of Vienna
University of Latvia
Austrian Science Fund (FWF)
Ministry of Health, Czech Republic
ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK (ECRIN)
German Federal Ministry of Research, Technology, and Space (BMFTR)
Deutsches Institut für Ernährungsforschung Potsdam-Rehbrücke (DIfE)
Latvian Council of Science
DLR Project Management Agency (DLR)
Czech Health Research Agency

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

March 1, 2027

Primary Completion (Estimated)

February 1, 2030

Study Completion (Estimated)

April 1, 2030

Study Registration Dates

First Submitted

July 14, 2026

First Submitted That Met QC Criteria

July 14, 2026

First Posted (Actual)

July 17, 2026

Study Record Updates

Last Update Posted (Actual)

July 20, 2026

Last Update Submitted That Met QC Criteria

July 17, 2026

Last Verified

July 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • U1111-1326-4843

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

Data Sharing Agreement still under negotiation

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity & Overweight

Clinical Trials on NutriAct plus

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Trinidad & Tobago

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe